Indication: Urothelial Carcinoma
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma
Advanced or metastatic
Sub-indication: Advanced or metastatic urothelial carcinoma
Line of Therapy: Cohort 1: Must have received prior chemotherapy which included a platinum agent. Cohort 2: Must have been ineligible for platinum-based chemotherapy.
Principal Investigator: Chandler Park, M.D.Norton Cancer Institute
Sponsor: Mirati Therapeutics, Inc
Email for more information: GU-NCIResearch@nortonhealthcare.org